Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, P.R. China.
First Clinical Medical College, Anhui Medical University, Meishan Road 81, Hefei, 230032, P.R. China.
Neurol Sci. 2024 Oct;45(10):4997-5002. doi: 10.1007/s10072-024-07553-1. Epub 2024 May 14.
Drug-resistant juvenile myoclonic epilepsy (DR-JME) remains a significant challenge in neurology. Traditional management strategies often fail to achieve satisfactory control, necessitating innovative treatments.
This case report aims to evaluate the efficacy and safety of deep brain stimulation (DBS) targeting the subthalamic nucleus (STN-DBS) in a patient with DR-JME.
We describe the treatment of a patient with DR-JME using STN-DBS. The patient underwent implantation and received high-frequency stimulation (HFS) at the STN.
One year post-implantation, the patient demonstrated a substantial reduction in motor seizure frequency by 87.5%, with improvements in quality of life and seizure severity by 52.0% and 46.7%, respectively. No adverse events were reported during the follow-up period.
This case represents the first report of favorable outcomes with STN-DBS in a patient with DR-JME, suggesting that long-term HFS of the STN may be a promising treatment option for patients suffering from this condition.
耐药性青少年肌阵挛性癫痫（DR-JME）仍然是神经科的一个重大挑战。传统的管理策略往往无法达到满意的控制效果，因此需要创新的治疗方法。
本病例报告旨在评估针对丘脑底核（STN）的深部脑刺激（DBS）治疗 DR-JME 患者的疗效和安全性。
我们描述了一位 DR-JME 患者使用 STN-DBS 的治疗情况。该患者接受了 STN 的植入和高频刺激（HFS）治疗。
植入后 1 年，患者的运动性癫痫发作频率显著减少了 87.5%，生活质量和癫痫严重程度分别改善了 52.0%和 46.7%。在随访期间没有报告不良事件。
本病例报告代表了首例使用 STN-DBS 治疗 DR-JME 患者的良好结果，表明 STN 的长期 HFS 可能是治疗这种疾病患者的一种有前途的治疗选择。
